關於癌症疫苗臨床前研究的業務進展更新 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：0775） 整體而言，所發表之研究均呈現一致主題：通過理性設計的癌症疫苗，於多個腫瘤靶點及疫苗構建 體之臨床前模型中，均展現強勁免疫原性及顯著的抗腫瘤活性。在發表中展示之該等數據充分印證 順譜醫藥科技從抗原篩選轉化至功能性免疫反應及腫瘤控制上之優勢。在此基礎上，順譜醫藥科技 正加快推進最具潛力之研發項目的新藥臨床試驗申請（IND）支持性研究，並期望透過策略性合作與 全球協作，加快將選定候選疫苗推進至早期臨床開發階段。 務請注意，該研究目前僅處於臨床前階段，本公司尚未開始就該等疫苗進行臨床試驗，故目前概不能 保證相關成果。因此，本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 長江生命科技集團有限公司 公司秘書 楊逸芝 香港，二零二六年三月三十一日 於本公告日期，本公司執行董事為李澤鉅先生（主席）、甘慶林 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 誠如先前公告所述，於二零二四年，本公司與一家專注研發舒緩痛楚及神經痛症藥物之納 斯達克上市公司 Dogwood Therapeutics, Inc.（「Dogwood」）完成交易。本公司現時持有 Dogwood 之多數股權。於二零二五年，本公司將處於後期研發階段之黑色素瘤疫苗 seviprotimut-L出售予另一家納斯達克上市公司 TransCode Therapeutics, Inc.（「TransCode」） 以獲取其股權。 隨 著 本公司持有 Sequencio 、 TransCode 及 Dogwood ， 本公司 已建立 研發平台， 其多元化研發組合涵蓋早期及後期項目，聚焦於當前醫療需求尚未得到充分滿足之領域。 承董事會命 長江生命科技集團有限公司 公司秘書 （於開曼群島註冊成立之有限公司） （股份代號：0775） 就成立順譜醫藥科技有限公司 以全力推進治療性癌症疫苗研發之 自願性公告 長江 ...

Core Viewpoint - Changjiang Life Sciences Technology (00775) has established a Scientific Advisory Committee to support its research projects, particularly in therapeutic cancer vaccines, amidst a complex global drug development environment [1][5]. Group 1: Company Developments - Changjiang Life Sciences Technology's stock price increased by 3.57% to HKD 0.87, with a trading volume of HKD 35.51 million [1][5]. - The newly formed Scientific Advisory Committee consists of independent experts from academia, clinical research, and industry, including notable figures such as former Secretary for Food and Health Ko Wing-man and clinical professor at HKU, Dr. Hsu Yi-wen [1][5]. Group 2: Strategic Initiatives - The committee is a strategic organization that will provide scientific, clinical, and regulatory guidance to accelerate the company's research projects, including several therapeutic cancer vaccines that are preparing for clinical trials [1][5]. - The Scientific Advisory Committee will also offer professional resources to help the company navigate the increasingly complex global drug development landscape, mitigate risks, and expedite regulatory approvals and patient access [1][5].

Core Viewpoint - Changjiang Life Sciences Technology (00775) has established a Scientific Advisory Committee to enhance its research capabilities and navigate the complexities of global drug development [1] Group 1: Company Developments - The stock of Changjiang Life Sciences Technology has seen an increase of over 4%, currently trading at 0.87 HKD with a transaction volume of 31.7098 million HKD [1] - The newly formed Scientific Advisory Committee consists of independent experts from academia, clinical research, and the industry, including notable figures such as former Secretary for Food and Health Ko Wing-man and clinical professor at HKU, Dr. Hsu Yi-wen [1] Group 2: Strategic Initiatives - The committee is a strategic organization aimed at providing scientific, clinical, and regulatory guidance to support the company's research projects, particularly in the development of therapeutic cancer vaccines [1] - The Scientific Advisory Committee will offer professional resources to help the company address the increasingly complex global drug development environment, mitigate risks, and expedite regulatory approvals and patient access [1]

Core Viewpoint - Changjiang Life Sciences Technology (00775) has established a Scientific Advisory Committee to enhance its research capabilities and navigate the complexities of global drug development [1] Group 1: Company Developments - Changjiang Life Sciences Technology's stock rose over 4%, currently trading at 0.87 HKD with a transaction volume of 31.7098 million HKD [1] - The newly formed Scientific Advisory Committee consists of independent experts from academia, clinical research, and the industry, including notable figures such as former Secretary for Food and Health Ko Wing-man and clinical professor at HKU, Dr. Hsu Yi-wen [1] - The committee will provide strategic guidance on scientific, clinical, and regulatory matters to support the company's research projects, particularly in the development of therapeutic cancer vaccines [1] Group 2: Strategic Implications - The establishment of the committee aims to mitigate risks and accelerate the process of obtaining regulatory approvals and patient access in an increasingly complex global drug development environment [1] - The committee will also offer professional resources to assist the company in advancing its research initiatives [1]

Core Insights - The Nipah virus has resurfaced in India, particularly in West Bengal, with 5 confirmed cases and around 100 individuals under home quarantine. This news has led to a rapid increase in the A-share market for flu and virus prevention sectors [1] - The vaccine ETF (159643) saw a net inflow of over 50 million yuan yesterday, indicating strong investor interest in vaccine-related investments [1] Industry Analysis - East Wu Securities highlights that the therapeutic cancer vaccine sector is entering a breakthrough development window, shifting the industry towards efficient and personalized immunotherapy [1] - mRNA vaccines possess three core competitive advantages over traditional technologies: rapid production capabilities and low costs, enhanced safety through non-integration with host genomes, and high flexibility in antigen design for personalized treatment [1] Investment Vehicle - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which selects listed companies involved in vaccine research, production, and related services from the Shanghai and Shenzhen markets, reflecting the overall performance of the vaccine industry chain [1]